PDCD1 and neoplasm: The results showed that, compared to the anti‐PD‐1 antibody alone, the combination of ML141 and the anti‐PD‐1 antibody significantly increased the expression of M1 markers and significantly reduced the expression of M2 markers in tumor‐associated macrophages (Figure S4).